Michael Levitt
InvestorAdvisory Board Member at LongeVC
About
Michael Levitt is a biophysicist and Nobel laureate (2013 Nobel Prize in Chemistry) whose research has focused on the molecular structure of biological compounds, protein folding, and computer modelling in biology, including the first computerised model of an enzyme reaction. He earned a bachelor's degree in Physics from King's College London (1967) and a doctorate in biophysics from the MRC Laboratory of Molecular Biology and the University of Cambridge (1971), and has held academic positions at the Weizmann Institute of Science and the MRC Laboratory. He has been a Professor of Structural Biology at Stanford University since 1987 and serves on LongeVC's Advisory Board.
Contact· self-published, not guessed
Invests in
BiotechLongevity
Colleagues at LongeVC
Alex Zhavoronkov
Venture Partner at LongeVC
Artem Trotsyuk
Operating Partner - US at LongeVC
Artemy Shumskiy
Principal at LongeVC
Christine Yuan Huang
Advisory Board at LongeVC
Dr. Weigao Wang
Venture Fellow at LongeVC
Evelyne Bischof
Venture Partner at LongeVC
Evgeny Izumchenko
Venture Partner at LongeVC
Garri Zmudze
Managing Partner at LongeVC
Frequently asked questions
- Who is Michael Levitt?
- Michael Levitt is a biophysicist and Nobel laureate (2013 Nobel Prize in Chemistry) whose research has focused on the molecular structure of biological compounds, protein folding, and computer modelling in biology, including the first computerised model of an enzyme reaction. He earned a bachelor's degree in Physics from King's College London (1967) and a doctorate in biophysics from the MRC Laboratory of Molecular Biology and the University of Cambridge (1971), and has held academic positions at the Weizmann Institute of Science and the MRC Laboratory. He has been a Professor of Structural Biology at Stanford University since 1987 and serves on LongeVC's Advisory Board.
- Where does Michael Levitt work?
- Michael Levitt is Advisory Board Member at LongeVC.
- What does Michael Levitt invest in?
- Michael Levitt invests in Biotech, Longevity.